title: Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".
authors.forename: Ahmad A
authors.initials: AA
authors.lastname: Tarhini
authors.forename: Janice
authors.initials: J
authors.lastname: Shipe-Spotloe
authors.forename: Melissa
authors.initials: M
authors.lastname: DeMark
authors.forename: Sanjiv S
authors.initials: SS
authors.lastname: Agarwala
authors.forename: John M
authors.initials: JM
authors.lastname: Kirkwood
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003657:Decision Making; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008545:Melanoma / Q000188:drug therapy*; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins